期刊文献+

雷帕霉素及其衍生物开发现状、作用机制及生物合成研究进展 被引量:7

Progress on development situation,mechanism and biosynthesis of rapamycin and its analogs
下载PDF
导出
摘要 目的介绍了近年来雷帕霉素及其衍生物的开发现状、作用机制与生物合成途径,探讨了通过前体定向生物合成与诱变生物合成的方式,获得雷帕霉素衍生物的研究进展,展望了雷帕霉素及衍生物的研究前景。方法分析、归纳、总结近年来发表的相关文献。结果与结论雷帕霉素及其衍生物是新型强效的免疫抑制剂与抗肿瘤药物,具有抗真菌、抗增殖及潜在延长哺乳动物寿命周期等作用。采用前体定向生物合成、诱变生物合成与组合生物合成的方式,可快速获得其具药理活性的衍生物。基于生物合成途径,采用系统生物学相关手段可获高产工程化菌种应用于工业化生产。 Objective The recent development situation, mechanism and biosynthesis of rapamycin and its derivatives were reviewed, and the research prospect of rapamycin and its analogs were further forecasted. Methods The literatures published in recent years were analyzed and summarized. Results and Conclusion Rapamycin and some its analogs are new potent immunosuppressive and anticancer drugs, which have obvious effects on anti-fungal, anti-proliferation, and the potential to extend the lifespan of mammalian and so on. By the ways of precursor-directed biosynthesis,mutational biosynthesis and combinatorial biosynthesis, some novel analogs of rapamycin can be obtained,and the high-yield strains tend to be reconstructed for industrial production by the means of system biology.
作者 李进 邹祥
机构地区 西南大学药学院
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2011年第11期806-813,共8页 Chinese Journal of Antibiotics
基金 国家新药创制重大专项项目(2010ZX09401-306-4-4) 重庆市创新能力建设项目(CSTC 2009 CB1010) 西南大学基本科研业务费科研项目(XDJK2009C175) 西南大学博士基金项目(SWU109034)
关键词 雷帕霉素 MTOR 生物合成 前体定向生物合成 诱变生物合成 Rapamycin mTOR Biosynthesis pathway Precursor-directed biosynthesis Mutational biosynthesis
  • 相关文献

参考文献36

  • 1Vezina C, Kudelsk A, Sehgal S N. Rapamycin (AY-22, 989), a new antifungal antibiotic[J].J.Antibiot, 1975, 10:721-726.
  • 2Nakao K, Yasuhiro K, Tatsuo S, et al. Novel rapamycin producer: European, 022446[P]. 1993-11-11.
  • 3Harrison D E, Strong R, Sharp Z D, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice[J]. Nature, 2009, 460: 392-395.
  • 4Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. NEnglJMed, 2007, 356: 2271-81.
  • 5Chan S, Scheulen M E, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer[J]. J Clin Oncol, 2005, 23:5314-5322.
  • 6Johnston P B, Inwards D J, Colgan J P, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma[J]. Am JHematol, 2010, 85(5): 320-324.
  • 7Rizzieri D A, Feldman E, DiPersio J F, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies[J]. Clin Cancer Res, 2008, 14(9): 2756-2762.
  • 8Chen Y W, Smith M L, Sheets M, et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression[J]. J Cardiovasc Pharmacol, 2007, 49: 228-235.
  • 9Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives[J]. Annals of Oncology, 2005, 16: 525-537.
  • 10Garcia J A, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies[J]. Mol Cancer Ther, 2008, 7: 1347-1354.

同被引文献25

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部